Oncology Institute Stock Technical Analysis
| TOI Stock | USD 4.03 0.01 0.25% |
As of the 13th of May 2026, Oncology Institute maintains a quoted price of 4.03 per share. Short-term indicators show Semi Deviation of 3.14, coefficient of variation of 624.13, and Risk Adjusted Performance of 0.1527. The model measures trend continuation and reversal probability using historical patterns. Price and volume patterns are measured against sector averages and recent history.
Oncology Institute Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Oncology, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to OncologyOncology |
Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 7.0 | Strong Buy | 1 | Odds |
Research provider recommendations for Oncology Institute are summarized in aggregate form. The consensus mean summarizes the distribution of analyst recommendations. Oncology Institute's analyst consensus is derived from the aggregate of buy, hold, and sell ratings issued by covering institutions. Consensus upgrades or downgrades for Oncology often have meaningful short-term impact on the stock price. Following analyst revisions on Oncology over time reveals trends in institutional sentiment. Consensus estimates serve as a benchmark for evaluating Oncology Institute's stock performance over time.
Earnings Share -0.35 | Revenue Per Share | Quarterly Revenue Growth 41.2% | Return On Assets | Return On Equity |
Book value captures Oncology accounting equity, while market value captures the collective view of participants. The interplay between these measures shapes how Oncology Institute is evaluated across frameworks.
Oncology Institute intrinsic value attempts to capture underlying worth, separate from current trading levels. For Oncology Institute, key inputs include a P/E ratio of 190.67, a P/B ratio of 0.76, a profit margin of -13.0%, and ROE of 4.05%.
What-If Analysis
What-if analysis for Oncology Institute is essentially a historical sensitivity test that shows how changes in the investment horizon could have altered realized return, drawdown, and timing outcomes. The analytical value is perspective: it shows whether the thesis would have remained investable across different historical windows or depended too heavily on one favorable stretch.
| 02/12/2026 |
| 05/13/2026 |
If you invested 0.00 in Oncology Institute on February 12, 2026 and closed the position today, you would produce 0.00 in aggregate gains. The net result is a 0.0% net return in Oncology Institute in total over the 90 day window. Oncology Institute has comparable peers such as Enhabit, Auna SA, Sonida Senior, Cross Country, Evolus, Treace Medical, and Orthopediatrics Corp. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States More
Oncology Institute Momentum Range Indicators Signals
Upside and downside measures for Oncology Institute frame directional pressure and range behavior. Upside potential is measured relative to recent highs; downside exposure is framed against recent lows.
| Downside Deviation | 3.85 | |||
| Information Ratio | 0.1616 | |||
| Maximum Drawdown | 26.29 | |||
| Value At Risk | -5.07 | |||
| Potential Upside | 8.4 |
Volatility and Risk Indicators for Oncology Institute Overview
Risk metrics describing Oncology Institute's historical price variability are presented below. Standard deviation of returns over multiple windows measures the magnitude of typical price swings.| Risk Adjusted Performance | 0.1527 | |||
| Jensen Alpha | 0.7795 | |||
| Total Risk Alpha | 0.8437 | |||
| Sortino Ratio | 0.2007 | |||
| Treynor Ratio | 0.517 |
Tracking mean reversion in Oncology Institute centers on spotting price extremes that have drifted well away from the historical norm. High prices relative to historical norms contrast with unusually low prices, where recovery expectations may emerge. Mean reversion in Oncology Institute is the opposite of trend following: it bets on reversals rather than riding momentum. Momentum identifies the trend while mean reversion identifies when it has extended beyond sustainable levels.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1527 | |||
| Market Risk Adjusted Performance | 0.527 | |||
| Mean Deviation | 3.53 | |||
| Semi Deviation | 3.14 | |||
| Downside Deviation | 3.85 | |||
| Coefficient Of Variation | 624.13 | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.8 | |||
| Information Ratio | 0.1616 | |||
| Jensen Alpha | 0.7795 | |||
| Total Risk Alpha | 0.8437 | |||
| Sortino Ratio | 0.2007 | |||
| Treynor Ratio | 0.517 | |||
| Maximum Drawdown | 26.29 | |||
| Value At Risk | -5.07 | |||
| Potential Upside | 8.4 | |||
| Downside Variance | 14.78 | |||
| Semi Variance | 9.85 | |||
| Expected Short fall | -4.33 | |||
| Skewness | 1.05 | |||
| Kurtosis | 3.09 |
Oncology Institute Backtested Returns
Oncology Institute shows an unstable price behavior relative to the chosen timeframe. It shows a risk-adjusted return measure of 0.2, defining risk-normalized returns. We identified thirty technical indicators influencing the company's volatility profile. Please evaluate metrics such as Semi Deviation of 3.14, coefficient of variation of 624.13, and risk-adjusted performance of 0.1527 to review standard deviation behavior. On a scale of 0 to 100, Oncology Institute holds a performance score of 16. The company holds a Beta (Market Risk) of 1.46, which means elevated sensitivity to broad market movements. Market upswings tend to lift Oncology Institute more than average, but downturns carry a proportionally larger impact on returns.
Auto-correlation | 0.81 |
Very good predictability
Oncology Institute shows very good predictability when comparing price series from 12th of February 2026 to 29th of March 2026 against from 29th of March 2026 to 13th of May 2026. A strong serial relationship would imply that Oncology Institute's recent trajectory contains information about its near-term direction. With a serial correlation of 0.81, around 81.0% of Oncology Institute's price variation is attributable to patterns in preceding intervals.
| Correlation Coefficient | 0.81 | |
| Spearman Rank Test | 0.68 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
This analysis reflects how Oncology Institute behaves based on price and volume data. The dataset includes signals based on trend and relative strength.
Technical Analysis
This analysis covers thirty-seven data points across the selected time horizon. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Oncology Institute volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of Oncology Institute evaluates price structure, momentum, and volatility clustering. Trend alignment improves interpretability of cross-signal confirmation. Oncology Institute has a market cap of 400.93 million, P/E of 190.67, ROE of -6.52%.
Oncology Institute metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Sell-side coverage, where present, supplements the data shown.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board
Technical Indicators
A technical review of Oncology Institute can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. Confirming one signal with others instead of reacting to one pattern in isolation improves the quality of the conclusion.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1527 | |||
| Market Risk Adjusted Performance | 0.527 | |||
| Mean Deviation | 3.53 | |||
| Semi Deviation | 3.14 | |||
| Downside Deviation | 3.85 | |||
| Coefficient Of Variation | 624.13 | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.8 | |||
| Information Ratio | 0.1616 | |||
| Jensen Alpha | 0.7795 | |||
| Total Risk Alpha | 0.8437 | |||
| Sortino Ratio | 0.2007 | |||
| Treynor Ratio | 0.517 | |||
| Maximum Drawdown | 26.29 | |||
| Value At Risk | -5.07 | |||
| Potential Upside | 8.4 | |||
| Downside Variance | 14.78 | |||
| Semi Variance | 9.85 | |||
| Expected Short fall | -4.33 | |||
| Skewness | 1.05 | |||
| Kurtosis | 3.09 |
May 13, 2026 Daily Trend Indicators
A technical review of Oncology Institute can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. Confirming one signal with others instead of reacting to one pattern in isolation improves the quality of the conclusion.
| Accumulation Distribution | 0.00 | ||
| Daily Balance Of Power | 1.00 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 4.03 | ||
| Day Typical Price | 4.03 | ||
| Price Action Indicator | 0.01 | ||
| Market Facilitation Index | 0.01 |